Novavax Gets the Job Done With its COVID Vaccine
In this video from Motley Fool Live recorded on Feb. 1, Fool.com contributors Brian Orelli and Keith Speights discussed phase 3 clinical trial data on Novavax's (NASDAQ: NVAX) coronavirus vaccine. The vaccine worked as well as the vaccine from Moderna (NASDAQ: MRNA) and the one from Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) against the original strain of the coronavirus. More importantly, Novavax's vaccine appears to protect participants from the U.K. variant, albeit to a lesser extent.
Source Fool.com